drugset / Trial / NCT01469377

Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder

NCT01469377

Phase 2 Completed 819 enrolled Forest Laboratories Gedeon Richter Ltd. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone. This clinical study compared cariprazine + ADT with placebo + ADT in outpatients with a diagnosis of MDD and an inadequate response to ADT. The study consisted of approximately 2 weeks of screening and washout followed by 8 weeks of double-blind treatment followed by a 1 week safety follow-up.

Timeline

Start
2011-12-15
Primary completion
2013-12-12
Completion
2013-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1 mg Oral
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 2 mg Oral
Subject Cariprazine Small molecule 3 mg Oral
Subject Cariprazine Small molecule 4.5 mg Oral